MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562245 | Name: RP5063 Hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RP5063 Hydrochloride is a multimodal serotonin receptor modulator.

Chemical Structure

RP5063 Hydrochloride
RP5063 Hydrochloride
CAS#1708960-04-6

Theoretical Analysis

MedKoo Cat#: 562245

Name: RP5063 Hydrochloride

CAS#: 1708960-04-6

Chemical Formula: C22H26Cl3N3O3

Exact Mass:

Molecular Weight: 486.81

Elemental Analysis: C, 54.28; H, 5.38; Cl, 21.85; N, 8.63; O, 9.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
RP5063 Hydrochloride; RP 5063 Hydrochloride; RP-5063 Hydrochloride; RP5063 HCl; RP 5063 HCl; RP-5063 HCl;
IUPAC/Chemical Name
6-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one hydrochloride
InChi Key
GMTQOJSRMVAFIF-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H25Cl2N3O3.ClH/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20;/h3-7,14H,1-2,8-13,15H2,(H,25,28);1H
SMILES Code
O=C1COC2=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C2N1.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 486.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bhat L, Hawkinson J, Cantillon M, Reddy DG, Bhat SR, Laurent CE, Bouchard A, Biernat M, Salvail D. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model. Eur J Pharmacol. 2018 Feb 14. pii: S0014-2999(18)30096-7. doi: 10.1016/j.ejphar.2018.02.017. [Epub ahead of print] PubMed PMID: 29453947. 2: Cantillon M, Bhat L. Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, MD, DrPh. Schizophr Res. 2018 Jan 21. pii: S0920-9964(17)30569-8. doi: 10.1016/j.schres.2017.09.010. [Epub ahead of print] PubMed PMID: 29395606. 3: Cantillon M, Ings R, Bhat L. Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients. Clin Transl Sci. 2017 Nov 8. doi: 10.1111/cts.12518. [Epub ahead of print] PubMed PMID: 29119704. 4: Aboraya A. Concerns about the design, analyses, and findings of the trial of dopamine serotonin stabilizer RP5063 by Cantillon and colleagues. Schizophr Res. 2017 Aug 25. pii: S0920-9964(17)30508-X. doi: 10.1016/j.schres.2017.08.034. [Epub ahead of print] PubMed PMID: 28847613. 5: Bhat L, Hawkinson J, Cantillon M, Reddy DG, Bhat SR, Laurent CE, Bouchard A, Biernat M, Salvail D. RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats. Eur J Pharmacol. 2017 Sep 5;810:92-99. doi: 10.1016/j.ejphar.2017.05.048. Epub 2017 May 31. PubMed PMID: 28577964. 6: Bhat L, Hawkinson J, Cantillon M, Reddy DG, Bhat SR, Laurent CE, Bouchard A, Biernat M, Salvail D. RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats. Eur J Pharmacol. 2017 Sep 5;810:83-91. doi: 10.1016/j.ejphar.2017.05.052. Epub 2017 May 31. PubMed PMID: 28576407. 7: Rajagopal L, Kwon S, Huang M, Michael E, Bhat L, Cantillon M, Meltzer HY. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. Behav Brain Res. 2017 Aug 14;332:180-199. doi: 10.1016/j.bbr.2017.02.036. Epub 2017 Mar 31. PubMed PMID: 28373127. 8: Cantillon M, Prakash A, Alexander A, Ings R, Sweitzer D, Bhat L. Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. Schizophr Res. 2017 Nov;189:126-133. doi: 10.1016/j.schres.2017.01.043. Epub 2017 Feb 16. PubMed PMID: 28215471.

View History

Ortho-AP1867

Ortho-AP1867

Featured